BioCryst Pharmaceuticals (NASDAQ:BCRX) Announces Quarterly Earnings Results

BioCryst Pharmaceuticals (NASDAQ:BCRX) issued its earnings results on Monday. The biotechnology company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.06), Zacks reports. The firm had revenue of $131.50 million during the quarter, compared to the consensus estimate of $130.05 million. During the same quarter last year, the company earned $0.28 EPS. BioCryst Pharmaceuticals’s revenue for the quarter was up 40.8% compared to the same quarter last year.

BioCryst Pharmaceuticals Stock Performance

Shares of NASDAQ:BCRX opened at $9.21 on Monday. The business has a fifty day moving average of $8.01 and a 200-day moving average of $7.84. BioCryst Pharmaceuticals has a twelve month low of $4.03 and a twelve month high of $9.50. The firm has a market cap of $1.91 billion, a PE ratio of -15.10 and a beta of 1.75.

Analysts Set New Price Targets

BCRX has been the subject of several recent research reports. JMP Securities reissued a “market outperform” rating and issued a $18.00 price target on shares of BioCryst Pharmaceuticals in a research note on Friday, January 31st. Barclays boosted their target price on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 5th. Royal Bank of Canada restated an “outperform” rating and set a $10.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. Evercore ISI lifted their price objective on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an “outperform” rating in a research note on Monday, January 13th. Finally, Needham & Company LLC increased their target price on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a “buy” rating in a research report on Monday, January 13th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $15.50.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.